Telix Pharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLPPF research report →
Range $20 – $20
Price Chart
About the company
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
- CEO
- Christian Behrenbruch
- IPO
- 2019
- Employees
- 1,184
- HQ
- North Melbourne, VIC, AU
Get TickerSpark's AI analysis on TLPPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.02B
- P/E
- 115.27
- Fwd P/E
- 252.39
- PEG
- -0.40
- P/S
- 4.12
- P/B
- 7.68
- EV/EBITDA
- 129.92
- Div Yield
- 0.00%
- Gross Margin
- 52.16%
- Op Margin
- -0.73%
- Net Margin
- 3.60%
- ROE
- 7.11%
- ROIC
- -0.58%
Latest fiscal year · YoY change
- Revenue
- $1.25B+59.1%
- Gross Profit
- $661.81M+29.8%
- Op Income
- $27.54M
- Net Income
- $-11,045,359-122.1%
- EPS
- $-0.03-121.8%
- OCF Growth
- -162.3%
- FCF Growth
- -1051.3%
- 52W High
- $12.50
- 52W Low
- $5.91
- 50D MA
- $10.64
- 200D MA
- $9.15
- Beta
- 0.60
- RSI (14)
- 64
- Avg Volume
- 3.24K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the TLPPF Q2 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 80.5%
- Shares Outstanding
- 338.78M
- Float Shares
- 272.81M
Our TLPPF coverage
Recent articles, reports, and earnings notes.
No research on TLPPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TLPPF report →Telix Seeks Reset With FDA Filing While Sales Growth Holds Steady
benzinga.com · Apr 10
Telix Pharmaceuticals: Solid Q1 As Pipeline And PSMA Franchise Drive Outlook
seekingalpha.com · Apr 8
Why Is Telix Pharma Stock Soaring Tuesday?
benzinga.com · Apr 7
Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Down 5.3% – Time to Sell?
defenseworld.net · Apr 2
Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript
seekingalpha.com · Mar 17
Telix Pharmaceuticals Limited (TLX) Discusses ProstACT Global Phase 3 Study Part 1 Results and Safety Profile Transcript
seekingalpha.com · Mar 10
Telix Pharmaceuticals Limited (TLX) Discusses Physician Perspectives on Innovations in PSMA PET CT Imaging for Prostate Cancer Transcript
seekingalpha.com · Mar 5
Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx
seekingalpha.com · Mar 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.